Compare FMN & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMN | PMVP |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 76.8M |
| IPO Year | N/A | 2020 |
| Metric | FMN | PMVP |
|---|---|---|
| Price | $11.03 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.3K | ★ 398.3K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.40 | $0.83 |
| 52 Week High | $11.38 | $1.88 |
| Indicator | FMN | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 53.42 |
| Support Level | $11.05 | $1.37 |
| Resistance Level | $11.10 | $1.51 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 18.42 | 42.42 |
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.